Prana Biotechnology Limited (A...

Prana Comments on Nature Medicine, PNAS and Journal of Alzheimer's Disease Articles That Highlight the Role of Metals in Neurological Diseases

Professor Rudy Tanzi Appointed Prana's Chief Scientific Advisor

Prana receives FDA approval to commence Huntington's Disease trial

FDA Approval to Commence Huntington's Disease Clinical Trial Using Prana's PBT2

Landmark Publication Endorses Prana's Drug Pipeline Strategy for Treating Neurodegenerative Diseases

Prana Biotech Begins Recruiting For Phase II Study Of PBT2 To Treat Alzheimer's

Prana commences Alzheimer's trial recruitment

Prana Commences Alzheimer's Trial Recruitment

Prana secures key patent for Parkinson's drug PBT434 in the U.S.

Prana Secures Key Patent for Parkinson's Drug PBT434 in the United States

Prana Biotechnology (PRAN) Receives Approval by Austin Health Research Ethics Committee for Alzheimer's Trial

Prana receives approval for Alzheimer's trial

Prana Receives Approval for Alzheimer's Trial

Prana says PBT2 reverses loss of synaptic activity in neurons

PRANA's PBT2 Reverses the Loss of Synaptic Activity in Neurons

Australian Federal Government Funds Study Into Neuroprotective Benefits of Prana's PBT2

Australian Federal Government Grant to Study Effect of PBT2 in the Ageing Brain

McNicoll Lewis & Vlak Starts Prana Biotechnology (PRAN) at Buy; Novel Therapeutic Approach to CNS Disorders: Neuronal Metal Homeostasis

Prana rises 18%

Prana announces Journal of Neurochemistry publication on PBT2

Prana's Planned Huntington's Trial Receives Strong Interest From Patients and Researchers

World Congress on Huntington's Learns About PBT2's Promise

PBT2 Huntington's Disease Trial Presented at World Congress on Huntington's Disease in Melbourne

Prana receives Michael J. Fox Foundation grant to develop PBT434 for Parkinson's

Prana Receives Michael J. Fox Foundation Grant to Develop PBT434 for Parkinson's Disease

Leading Biotechnology Investor Lawrence Gozlan Joins Prana's Board of Directors

PBT2's 'Mechanism of Action' Presented in a Plenary Lecture at International Conference on Alzheimer's Disease (ICAD) on July 21 in Paris

files to sell up to 5M ADS through at-the-market offering

Prana Announces At-The-Market Issuance Program

Quintiles Makes Second Investment in Prana

Prana's PBT2 Presented at the Huntington's Disease Society of America National Convention

Rodman & Renshaw Provides Color on Prana Biotechnology, Market Outperform

Prana's Founding Scientists Present Findings at World Pharma Congress

Prana Biotech (PRAN) Files $50M Mixed Securities Shelf

Prana files $50M mixed securities shelf

Prana Biotechnology (PRAN) Accelerates PBT2 Commercial Development

Prana Accelerates PBT2 Commercial Development

Rich Pipelines Send Biotech Stocks Soaring

Prana Secures Key PBT2 Patent in Japan and Completes Core IP Suite

Prana secures PBT2 patent in Japan